Abstract Number: 83 • 2019 ACR/ARP Annual Meeting
Dysfunction of TRIM21 Promotes Aberrant Plasmablast Differentiation in Systemic Lupus Erythematosus Due to the Reduction of TRIM21-mediated Ubiquitylation of IRF5
Background/Purpose: TRIM21 is a member of the tripartite motif family proteins and is one of the autoantigens which react with anti-SS-A antibody (Ab) present in…Abstract Number: 659 • 2019 ACR/ARP Annual Meeting
Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity
Background/Purpose: B-cells play a pivotal role in the initiation and perpetuation of systemic lupus erythematosus (SLE). Recently, it has been demonstrated that in active SLE…Abstract Number: 862 • 2019 ACR/ARP Annual Meeting
First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study
Background/Purpose: Aberrantly activated T- and B-lymphocytes play a major pathophysiological role in SLE. Cenerimod, a potent, selective sphingosine-1-phosphate 1 receptor modulator, blocks the egress of…Abstract Number: 1035 • 2019 ACR/ARP Annual Meeting
Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects females (9:1) over males. Despite significant research effort, the exact mechanisms behind this compelling sex bias are undefined.…Abstract Number: 1395 • 2019 ACR/ARP Annual Meeting
Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab
Background/Purpose: The most widely used B cell targeted therapies in auto-immune diseases (AID) is Rituximab (RTX), a murine chimeric monoclonal antibody. Among RTX’s side effects,…Abstract Number: 1592 • 2019 ACR/ARP Annual Meeting
Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in SLE patients. Hypocomplementemia, antiphospholipid antibodies, and elevated antibodies to RNP and Ro are…Abstract Number: 1627 • 2019 ACR/ARP Annual Meeting
Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
Background/Purpose: To evaluate the pathogens from bronchoalveolar lavage fluid (BALF) and risk factors of mortality in SLE patients with pneumonia and respiratory failure.Methods: Twenty-four SLE…Abstract Number: 1936 • 2019 ACR/ARP Annual Meeting
The Expression of the Interferon Inducible Gene SERPING1 Is Reduced by Rituximab and Correlates with Clinical Response in Systemic Lupus Erythematosus
Background/Purpose: Abnormalities in B cells and the interferon alpha (IFN) pathway have been separately implicated in the pathogenesis of systemic lupus erythematosus (SLE). B cell…Abstract Number: 2251 • 2019 ACR/ARP Annual Meeting
Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study
Background/Purpose: Systemic lupus erythematosus (SLE) poses complex diagnostic and management challenges, which may differ depending on whether SLE was diagnosed in childhood (cSLE) or in…Abstract Number: 2532 • 2019 ACR/ARP Annual Meeting
Effect of Treatment on Antiphospholipid Antibodies in SLE
Background/Purpose: Unlike primary antiphospholipid syndrome patients, most SLE patients with antiphospholipid antibodies are on one or more treatments for their SLE that might affect levels…Abstract Number: 2566 • 2019 ACR/ARP Annual Meeting
Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE
Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds), is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially…Abstract Number: 2814 • 2019 ACR/ARP Annual Meeting
Methionine Commits Immunometabolism and Epigenetic Regulation of BACH2 Loci in B Cells, Resulting in Biases Toward Plasmablast Differentiation in the Pathogenesis of SLE
Background/Purpose: Amino acids play an important role in various metabolic processes. However, the role of amino acid metabolism in the regulation of human B cell…Abstract Number: 85 • 2019 ACR/ARP Annual Meeting
Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model
Background/Purpose: The immunoproteasome is a distinct class of proteasome found predominantly in immune effector cells and has been shown to play a distinct role in…Abstract Number: 661 • 2019 ACR/ARP Annual Meeting
Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: TWEAK, MCP-1 and NGAL, mediators in pathogenesis of systemic lupus erythematosus (SLE), are proinflammatory cytokines/chemokines that are thought as potential biomarkers reflecting disease activity.…Abstract Number: 883 • 2019 ACR/ARP Annual Meeting
B Cell-specific MyD88 Regulates Pathology After Disease Onset in Murine Lupus
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease defined by immune dysregulation, antibody formation, followed by end-organ damage. MyD88 is a central immune…
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 150
- Next Page »